Astellas Pharma Inc.
4503.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -2.09 | -1.81 | 8.60 |
| FCF Yield | 6.36% | 3.06% | 6.98% | 5.12% |
| EV / EBITDA | 13.02 | 18.49 | 13.52 | 14.24 |
| Quality | ||||
| ROIC | 10.05% | 4.39% | 11.70% | 9.56% |
| Gross Margin | 74.59% | 81.76% | 81.01% | 80.48% |
| Cash Conversion Ratio | 3.97 | 10.12 | 2.48 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.99% | 7.35% | 6.72% | -0.12% |
| Free Cash Flow Growth | 82.94% | -62.39% | 32.17% | -21.10% |
| Safety | ||||
| Net Debt / EBITDA | 2.59 | 3.43 | -0.74 | -0.43 |
| Interest Coverage | 14.46 | 19.01 | 32.51 | 44.46 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 1.18 | 1.65 | 1.65 |
| Cash Conversion Cycle | 205.53 | 201.06 | 146.09 | 139.92 |